成人与儿童免疫性血小板减少症中的危重出血:一项多中心队列研究
该回顾性队列研究纳入美国和加拿大7个中心2010至2019年间因免疫性血小板减少症(ITP)就诊于急诊且血小板计数<20×10^9/L的1226例患者(成人296例,儿童930例),其中28例(2.3%)发生危重出血。危重出血罕见但常致命,尤其见于合并颅内出血的老年成人及治疗延迟时。
要点
- 1226例ITP患者中28例(2.3%)发生危重出血,成人15例,儿童13例。
- 危重出血患者中,成人12例(80.0%)和儿童6例(46.2%)为颅内出血。
- 危重出血患者中9例(32.1%)死亡,包括成人7例(46.7%)和儿童2例(15.4%)。
核心结论
- ITP患者危重出血罕见但常致命,尤其见于合并颅内出血的老年成人及治疗延迟时。
研究设计与样本
- 回顾性队列研究,纳入美国和加拿大7个中心2010至2019年间因ITP就诊于急诊且血小板计数<20×10^9/L的患者1226例(成人296例,儿童930例)。
主要发现
- 1226例患者中28例(2.3%)发生危重出血,其中成人15例(中位年龄68岁),儿童13例(中位年龄11岁)。
- 危重出血患者中,成人12例(80.0%)和儿童6例(46.2%)发生颅内出血。
- 成人危重出血常用干预为血小板输注11例(73.3%)、糖皮质激素10例(66.7%)和静脉注射免疫球蛋白8例(53.3%);儿童常用干预为静脉注射免疫球蛋白10例(76.9%)、糖皮质激素8例(61.5%)、血小板输注8例(61.5%)、血小板生成素受体激动剂4例(30.8%)和抗纤溶药物4例(30.8%)。
- 成人和儿童最常见的联合治疗均为糖皮质激素+静脉注射免疫球蛋白+血小板输注(成人6例[40.0%] vs 儿童6例[46.2%])。
- 从就诊至首次治疗的中位时间成人6.9小时,儿童3.5小时;危重出血患者中9例(32.1%)死亡,包括成人7例(46.7%)和儿童2例(15.4%)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Critical bleeding in patients with immune thrombocytopenia (ITP) is a life-threatening hematologic emergency. This study aimed to describe the frequency, management, and outcomes of critical bleeds among adults and children with ITP. We conducted a retrospective cohort study of patients with ITP who presented to the emergency room with a platelet count <20 × 109/L across 7 centers in the United States and Canada between 2010 and 2019. Of 1226 patients (n = 296 adults; n = 930 children), 28 (2.3%) had critical bleeds (adults, n = 15 [median age, 68 years]; children, n = 13 [median age, 11 years]). Of patients with critical bleeds, 12 adults (80.0%) and 6 children (46.2%) had intracranial hemorrhage (ICH). For adults, the common interventions used to treat critical bleeds were platelet transfusions (n = 11 [73.3%]), corticosteroids (n = 10 [66.7%]), and IV immunoglobulin (n = 8 [53.3%]), and for children, common interventions were IV immunoglobulin (n = 10 [76.9%]), corticosteroids (n = 8 [61.5%]), platelet transfusions (n = 8 [61.5%]), thrombopoietin receptor agonists (n = 4 [30.8%]), and antifibrinolytic agents (n = 4 [30.8%]). For both adults and children, the most common treatment combination was corticosteroids, IV immunoglobulin, and platelet transfusion (n = 6 [40.0%] vs n = 6 [46.2%]). The median time from presentation to first treatment was 6.9 hours for adults and 3.5 hours for children. Overall, 9 patients (32.1%) with critical ITP bleeds died, including 7 adults (46.7%) and 2 children (15.4%). Critical bleeding in patients with ITP was rare but frequently fatal, especially among older adults with ICH and when treatments were delayed.
引用
- Sirotich E, Chowdhury SR, Modi D, et al. Critical bleeding in adults and children with immune thrombocytopenia: a multicenter cohort study. Blood Adv. 2025. PMID: 40203187. doi:10.1182/bloodadvances.2024015494
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。